Key statistics
As of last trade, Novocure Ltd (NVCR:NSQ) traded at 12.75, 29.84% above the 52 week low of 9.82 set on Feb 09, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 12.88 |
|---|---|
| High | 12.99 |
| Low | 12.47 |
| Bid | 12.75 |
| Offer | 12.79 |
| Previous close | 13.52 |
| Average volume | 2.92m |
|---|---|
| Shares outstanding | 113.79m |
| Free float | 100.98m |
| P/E (TTM) | -- |
| Market cap | 1.54bn USD |
| EPS (TTM) | -1.22 USD |
Data delayed at least 15 minutes, as of Mar 03 2026 14:40 GMT.
More ▼
- Novocure Announces Optune Lua® Receives Reimbursement Approval in Japan for the Treatment of Non-Small Cell Lung Cancer
- Novocure to Participate in 2026 Leerink Global Healthcare Conference
- Novocure Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Company Update
- Tumor Treating Fields (TTFields) Therapy to be Covered for Patients with Newly Diagnosed Glioblastoma Through British Columbia Cancer (BC Cancer)
- U.S. FDA Approves Novocure’s Optune Pax® for the Treatment of Locally Advanced Pancreatic Cancer
- Novocure Announces Preliminary Full Year and Fourth Quarter 2025 Performance and Provides Company Update
- Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference
More ▼
